[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100656137":3},{"organization":4,"outcomesModule":7,"designInfo":115,"detailedDescription":11,"studyPopulation":11,"armGroups":126,"interventions":139,"overallOfficials":151,"centralContacts":155,"locations":160,"responsibleParty":216,"collaborators":11,"id":218,"slug":219,"hasResults":220,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":11,"eligibilityCriteria":224,"healthyVolunteers":220,"sex":225,"minAge":226,"maxAge":11,"enrollmentInfo":227,"targetDuration":11,"studyType":230,"phases":231,"briefSummary":233,"conditions":234,"keywords":238,"overallStatus":187,"whyStopped":11,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":252},{"fullName":5,"class":6},"Pfizer","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Change From Baseline in Apnea-Hypopnea Index (AHI)",null,"baseline, Week 52",[14,17,20,23,26,28,31,33,36,39,41,43,45,47,49,51,53,55,57,59,62,64,67,69,71,73,75,77,79,81,83,85,87,89,91,93,95,97,99,101,103,105,107,109,111,113],{"measure":15,"description":11,"timeFrame":16},"Percent Change From Baseline in Body Weight","Baseline, Week 52",{"measure":18,"description":11,"timeFrame":19},"Change From Baseline in High-Sensitivity C-Reactive Protein (hs-CRP)","Baseline , week 52",{"measure":21,"description":11,"timeFrame":22},"Percent change from baseline in AHI","Baseline, week 52",{"measure":24,"description":11,"timeFrame":25},"Percentage of participants with ≥ 50% AHI reduction","baseline ,week 52",{"measure":27,"description":11,"timeFrame":22},"Change From Baseline in Sleep Apnea Specific Hypoxic Burden (SASHB)",{"measure":29,"description":11,"timeFrame":30},"Percentage of participants who achieve either AHI \u003C5 events\u002Fhour or AHI 5-14 events\u002Fhour with Epworth Sleepiness Scale (ESS) score ≤10","baseline, week 52",{"measure":32,"description":11,"timeFrame":22},"Change From Baseline in Systolic Blood Pressure (SBP)",{"measure":34,"description":35,"timeFrame":30},"Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment 8a T-score","Change from baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment Short Form 8a T-score. Higher scores indicate greater sleep-related impairment..",{"measure":37,"description":38,"timeFrame":22},"Change From Baseline in PROMIS Sleep Disturbance 8b T-score","Change from baseline in the PROMIS Sleep Disturbance Short Form 8b T-score. Higher scores indicate greater sleep disturbance.",{"measure":40,"description":11,"timeFrame":22},"Change from baseline in Impact of Weight on Quality of Life-Lite Clinical Trials (IWQOL-Lite-CT) Physical Function Composite Score",{"measure":42,"description":11,"timeFrame":22},"Percentage of participants with apnea-hypopnea events less then 15",{"measure":44,"description":11,"timeFrame":22},"Change From Baseline in Epworth Sleepiness Scale Total Score",{"measure":46,"description":11,"timeFrame":22},"Change from baseline in IWQoL-Lite-CT physical function composite score",{"measure":48,"description":11,"timeFrame":22},"Change From Baseline in IWQOL-Lite-CT Physical Composite Score",{"measure":50,"description":11,"timeFrame":22},"Change from baseline in IWQoL-Lite-CT Psychosocial Composite Score",{"measure":52,"description":11,"timeFrame":22},"Change From Baseline in IWQoL-Lite-CT Total Score",{"measure":54,"description":11,"timeFrame":22},"Change From Baseline in Body Weight",{"measure":56,"description":11,"timeFrame":22},"Change From Baseline in Body Mass Index (BMI)",{"measure":58,"description":11,"timeFrame":22},"Change From Baseline in Waist Circumference",{"measure":60,"description":11,"timeFrame":61},"Change From Baseline in Neck Circumference","Baseline, wee 52",{"measure":63,"description":11,"timeFrame":22},"Change From Baseline in Short Form 36-Item ((SF-36)",{"measure":65,"description":11,"timeFrame":66},"Percentage of Participants With Improvement in Patient Global Impression of Severity (PGI-S) Sleepiness Category","Week 52",{"measure":68,"description":11,"timeFrame":66},"Percentage of Participants With Improvement in Patient Global Impression of Severity (PGI-S) Fatigue Category",{"measure":70,"description":11,"timeFrame":61},"Percentage of Participants With Improvement in Patient Global Impression of Severity (PGI-S) Snoring Category",{"measure":72,"description":11,"timeFrame":66},"Percentage of Participants Reporting Improvement in Patient Global Impression of Change (PGI-C) Sleepiness",{"measure":74,"description":11,"timeFrame":66},"Percentage of Participants Reporting Improvement in Patient Global Impression of Change (PGI-C) Fatigue",{"measure":76,"description":11,"timeFrame":66},"Percentage of Participants Reporting Improvement in Patient Global Impression of Change (PGI-C) Sleep Quality",{"measure":78,"description":11,"timeFrame":66},"Percentage of Participants Reporting Improvement in Patient Global Impression of Change (PGI-C) Snoring",{"measure":80,"description":11,"timeFrame":22},"Change From Baseline in EuroQol 5-Dimension, 5-Level (EQ-5D-5L) Index Score",{"measure":82,"description":11,"timeFrame":22},"Change From Baseline in EuroQol-visual analog scale (EQ-VAS) Score",{"measure":84,"description":11,"timeFrame":22},"Change From Baseline in Work Productivity and Activity Impairment - General Health (WPAI:GH) Absenteeism Score",{"measure":86,"description":11,"timeFrame":22},"Change From Baseline in WPAI:GH Presenteeism Score",{"measure":88,"description":11,"timeFrame":22},"Change From Baseline in WPAI:GH Work Productivity Loss Score",{"measure":90,"description":11,"timeFrame":22},"Change From Baseline in WPAI:GH Activity Impairment Score",{"measure":92,"description":11,"timeFrame":66},"Number of participants with Treatment-Emergent Adverse Event (TEAE)",{"measure":94,"description":11,"timeFrame":66},"Number of participants with Serious Adverse Event (SAE)",{"measure":96,"description":11,"timeFrame":66},"Number of participants with Adverse event (AE) leading to permanent discontinuation from study intervention or study",{"measure":98,"description":11,"timeFrame":66},"Number of participants with Adverse Events of Special Interest (AESI)",{"measure":100,"description":11,"timeFrame":66},"Number of participants with clinical laboratory abnormalities",{"measure":102,"description":11,"timeFrame":22},"Change From Baseline in Diastolic Blood Pressure",{"measure":104,"description":11,"timeFrame":22},"Change From Baseline in Total Cholesterol",{"measure":106,"description":11,"timeFrame":22},"Change From Baseline in High-density lipoprotein cholesterol (HDL-C)",{"measure":108,"description":11,"timeFrame":22},"Change From Baseline in Low-density lipoprotein cholesterol (LDL-C)",{"measure":110,"description":11,"timeFrame":22},"Change From Baseline in Non-HDL Cholesterol",{"measure":112,"description":11,"timeFrame":22},"Change From Baseline in Very low-density lipoprotein cholesterol (VLDL) Cholesterol",{"measure":114,"description":11,"timeFrame":22},"Change From Baseline in Triglycerides",{"allocation":116,"interventionModel":117,"interventionModelDescription":11,"primaryPurpose":118,"observationalModel":11,"timePerspective":11,"maskingInfo":119},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":120,"maskingDescription":11,"whoMasked":121},"QUADRUPLE",[122,123,124,125],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[127,133],{"label":128,"type":129,"description":130,"interventionNames":131},"Treatment Arm","EXPERIMENTAL","Participants will receive berobenatide by Subcutaneous Injection.",[132],"Drug: Berobenatide",{"label":134,"type":135,"description":136,"interventionNames":137},"Placebo","PLACEBO_COMPARATOR","Participants will receive matching placebo by Subcutaneous Injection.",[138],"Other: Placebo",[140,148],{"type":141,"name":142,"description":143,"armGroupLabels":144,"otherNames":145},"DRUG","Berobenatide","By Subcutaneous Injection",[128],[146,147],"MET-097i","PF-08653944",{"type":149,"name":134,"description":143,"armGroupLabels":150,"otherNames":11},"OTHER",[134],[152],{"name":153,"affiliation":5,"role":154},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[156],{"name":153,"role":157,"phone":158,"phoneExt":11,"email":159},"CONTACT","1-800-718-1021","ClinicalTrials.gov_Inquiries@pfizer.com",[161,175,185,196,206],{"facility":162,"status":163,"city":164,"state":165,"zip":166,"country":167,"countryCode":168,"cosmosGeoPoint":169,"geoPoint":174,"contacts":11},"Cullman Clinical Trials","NOT_YET_RECRUITING","Cullman","Alabama","35055","United States","US",{"type":170,"coordinates":171},"Point",[172,173],-86.84361,34.17482,{"lat":173,"lon":172},{"facility":176,"status":163,"city":177,"state":178,"zip":179,"country":167,"countryCode":168,"cosmosGeoPoint":180,"geoPoint":184,"contacts":11},"Probe Clinical Research Corporation","Riverside","California","92501",{"type":170,"coordinates":181},[182,183],-117.39616,33.95335,{"lat":183,"lon":182},{"facility":186,"status":187,"city":188,"state":189,"zip":190,"country":167,"countryCode":168,"cosmosGeoPoint":191,"geoPoint":195,"contacts":11},"DM Clinical Research","RECRUITING","Bradenton","Florida","34209",{"type":170,"coordinates":192},[193,194],-82.57482,27.49893,{"lat":194,"lon":193},{"facility":197,"status":187,"city":198,"state":199,"zip":200,"country":167,"countryCode":168,"cosmosGeoPoint":201,"geoPoint":205,"contacts":11},"Headlands Research - Twin Cities","Maplewood","Minnesota","55109",{"type":170,"coordinates":202},[203,204],-92.99522,44.95302,{"lat":204,"lon":203},{"facility":207,"status":163,"city":208,"state":209,"zip":210,"country":167,"countryCode":168,"cosmosGeoPoint":211,"geoPoint":215,"contacts":11},"Velocity Clinical Research, Dallas","Dallas","Texas","75230",{"type":170,"coordinates":212},[213,214],-96.80667,32.78306,{"lat":214,"lon":213},{"type":217,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100656137","phase-3-a-study-to-learn-about-the-monthly-dosing-study-medicine-called-berobenatide-in-adults-with-breathing-problems-during-sleep-and-overweight-or-obesity-who-use-a-breathing-machine-pap-vesper-osa-1-100656137",false,"NCT07823608","A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)","A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH OBSTRUCTIVE SLEEP APNEA AND OVERWEIGHT OR OBESITY RECEIVING POSITIVE AIRWAY PRESSURE THERAPY (VESPER-OSA 1)","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Body mass index (BMI) ≥27 kg\u002Fm² at screening\n* Previously diagnosed with moderate to severe obstructive sleep apnea (OSA)\n* Ongoing positive airway pressure (PAP) therapy for obstructive sleep apnea that is expected to continue during the study.\n\nExclusion Criteria:\n\n* Self-reported body weight change of more than 5% within 90 days prior to screening\n* Diagnosis of any type of diabetes (resolved gestational diabetes is permitted)\n* History of acute or chronic pancreatitis\n* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2) Sleep-disordered breathing conditions other than obstructive sleep apnea that could interfere with study assessments or interpretation of results (eg, central sleep apnea, mixed sleep apnea, Cheyne-Stokes respiration, obesity hypoventilation syndrome, or significant craniofacial abnormalities).","ALL","18 Years",{"count":228,"type":229},258,"ESTIMATED","INTERVENTIONAL",[232],"PHASE3","This study is being done to learn about the safety and effects of a study medicine called berobenatide (bear-oh-BEN-uh-tide). The study will see if berobenatide can help adults with breathing problems during sleep (obstructive sleep apnea \\[OSA\\]) and overweight or obesity who use a breathing machine (positive airway pressure \\[PAP\\] machine).\n\nPeople may be able to take part if they are adults with moderate to severe OSA, have overweight or obesity, and have been using PAP therapy before joining the study. Participants will be assigned by chance to receive either berobenatide or a placebo (a treatment that looks like the study medicine but contains no active medicine). The study treatment will be given as an injection under the skin approximately once a month. Participants will receive study treatment at study sites and may administer some doses at home after receiving training.\n\nDuring the study, participants will attend study visits, undergo sleep studies, complete questionnaires, and have health assessments performed. Researchers will compare the effects of berobenatide and placebo on sleep apnea, body weight, and other health measures.",[235,236,237],"Apnea","Sleep Disorders","Overweight and\u002For Obesity",[239,240,241,236,242],"Sleep Apnea","Obesity","Overweight","Vesper","2026-10-05",{"date":245,"type":246},"2026-10-08","ACTUAL",{"date":248,"type":246},"2026-09-17",{"date":250,"type":229},"2028-06-18",{"name":5,"class":6},5]